Loading in 2 Seconds...
Loading in 2 Seconds...
LABORATORY OF RETROVIRUS RESEARCH DIVISION OF VIRAL PRODUCTS Site Visit 11 th June, 2009 OVERVIEW LRR PRINCIPAL INVESTIGATORS Hana Golding, Ph.D. (PI and Lab Chief) Unit of Viral Immunology and Pathogenesis Keith Peden, Ph.D. (PI) Unit of Cell Biology and Molecular Genetics
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Site Visit 11th June, 2009
Unit of Viral Immunology and Pathogenesis
Unit of Cell Biology and Molecular Genetics
Unit of Molecular Retrovirology
WHO CONSULTATIONS AND VRBPAC PRESENTATIONS
WORKSHOPS (Co-organized & Presenters):
HIV-1, Influenza, and Smallpox vaccines; Development of new assays and animal models for evaluation of vaccine safety and efficacy
Development of quantitative in vitro and in vivo assays to evaluate the safety of novel cell substrates for vaccine production
Development of sensitive assays for detection of latent viruses in vaccine cell substrates and risk-assessment of human infections with agents of potential concern
S. Khurana et al. 2006. A novel assay for diagnosis of HIV infections in the presence of
antibodies induced by candidate HIV preventive vaccine J. Virol 80:2092
S. Khurana et al. 2006. Novel approach for differential diagnosis of HIV infections in the face of
vaccine generated antibodies: Utility for detection of diverse HIV-1 subtypes. J. Acquired
S. Khurana et al. 2009. HIV-SELECTEST EIA and Rapid Test: Utility for detection of seroconversion
following acute HIV-1 infections J. Clin. Microb. (in press)
The HIV SELECTEST (EIA and Rapid test) is currently being developed for
licensure by two companies under a three year contract from the NHBLI
II. Pandemic influenza preparedness: Development of new molecular
tools for the evaluation of antibody repertoires in vaccine recipients
and H5N1 recovered individuals
S. Khurana, A.L. Suguitan Jr, Y. Rivera, C. P. Simmons, A. Lanzavecchia, F. Sallusto, J. Manischewitz, L.R. King, K. Subbarao and H. Golding. 2009. Antigenic fingerprinting of an H5N1 avian influenza virus using convalescent sera and human monoclonal antibodies reveals potential vaccine and serodiagnostic targets. PLoS Med 6(4): e1000049
S. Khurana, W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. Del Giudice, R. Rappouli, and H. Golding 2009. MF59 adjuvanted vaccines expand antibody repertoires targeting protective sites of pandemic influenza virus Science Translational Medicine (in press)
III.BioDefense project: In vivo reporter gene-based assay for comparative evaluation of novel prophylactic smallpox vaccines and therapies in small animal models
M. Zaitseva, S.M. Kapnick, J. Scott, L. R. King, J. Manischewitz, L. Sirota, and H. Golding 2009.Application of bioluminescence imaging to the prediction of lethality in vaccinia virus infectedmice J. Virol. 83:10437–10447.
Novel Vaccine Adjuvants( manuscripts in preparation):
Development of in vitro Human Cell Line-based assays predictive of in vivo toxicities of adjuvants
Validation of new biomarkers for preclinical evaluation of novel adjuvants in rabbits
CELL SUBSTRATE AND VACCINE SAFETY
STUDIES OF SIMIAN FOAMY VIRUS (SFV) TO EVALUATE IMPACT ON PRECLINICAL
VACCINE STUDIES IN NHPs AND RISK OF HUMAN INFECTIONS
IV. Investigation of SFV latency and replication by in vitro functional analysis of regulatory elements using different SFV isolates identified role of internal promoter and transactivator protein (Tas) in cell-specific replication and efficiency of virus replication, respectively.
• Ma, Y.K. and Khan, A.S. Evaluation of different RT enzyme standards for quantitation of
retroviruses using the single-tube fluorescent product-enhanced reverse transcriptase assay.
J. Virol. Methods 157:133-140, 2009
• Khan, A.S. Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates
by chemical induction. Biologicals 37: 196-201, 2009
• Khan, A.S. Simian foamy virus infection in humans. Prevalence and management. Expert Rev.
Anti Infect. Ther. 7: 569-580, 2009
• Khan, A.S. Characterization and qualification of cell substrates for manufacture of viral vaccines
in the United States. BioProcessing Journal. 8- 12, 2009
• Williams, D.K. and Khan A.S. 2009 Role of neutralizing antibodies in controlling simian foamy
virus transmission and infection. Transfusion Aug. 28, 2009 (Epub ahead of print)
• Galvin, T.A. Shahabuddin, M., Bryan, T., Sears, J.F., Viswanathan, K., Kaushal, M., and Khan,
A.S. Evaluation of transcriptional regulatory elements in two simian foamy virus serotypes
reveals difference in Tas activity. Re-submitted addressing reviewer’s comments
• Ma, H., Ma, Y, Ma, W, Williams, D.k., Galvin, T.A, Baptista, C.S., Sotelo-Silveira, J., Munroe,
D.J, and Khan, A.S. Endogenous retrovirus particles induced from the VERO cell line of African
green monkeys. Re-submitted addressing reviewer’s comments